Partnering

Cloud Pharmaceuticals has over 20 early stage drug programs in discovery, preclinical research and animal studies, both directly and in partnership with academic and commercial organizations.  A portion of its programs include:
​

• A beta-CR peptide inhibitor with promising animal data, suitable for reducing chemotherapy side effects
• A pro-drug design for Crohn's Disease
• A novel drug candidate for Dengue fever
• Several cancer drug candidates for novel targets, including, but not limited to Metnase, DNA polymerase beta and PD-1
• A selective small molecule inhibitor for PDHK2 for Congenital pyruvate dehydrogenase complex (PDC) deficiency
• Several clinical stage rare disease assets discovered with AI to repurpose existing drugs
• A Phase 2 stage thrombosis drug program